Neuroectodermal Tumors, Primitive clinical trials

The registry lists 120 studies for Neuroectodermal Tumors, Primitive across more than 10 countries. 22 are recruiting or about to start. 13 of them are mainly about Neuroectodermal Tumors, Primitive (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-09. Counting its 5 narrower conditions too, such as Neuroblastoma: 1,094 studies, 189 open.

Get an email when these change. Save the Neuroectodermal Tumors, Primitive studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies

See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed: 64
Recruiting: 19
Terminated: 15
Active, not recruiting: 7
Withdrawn: 6
Status unknown: 5

Phase

Phase 1: 54
Phase 2: 41
Phase 3: 7
Early Phase 1: 1

Where

United States: 100
France: 13
Canada: 9
Spain: 8
Italy: 8
Netherlands: 7

Who runs them

National Cancer Institute (NCI) (14) · Novartis Pharmaceuticals (6) · M.D. Anderson Cancer Center (6) · Wake Forest University Health Sciences (5) · Burzynski Research Institute (4) · City of Hope Medical Center (3) · Seattle Children's Hospital (3) · Case Comprehensive Cancer Center (3)

What is being tested here

Drugs under test in Neuroectodermal Tumors, Primitive studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug	Open	Phase 3	All
Cyclophosphamide	2	0	5
Temozolomide	1	0	7
Etoposide	1	0	3
G 207	1	0	2
Oncolytic HSV-1 G207	1	0	2
Fludarabine	1	0	2
Zoledronic Acid	1	0	1
Ersodetug	1	1	1
Belzutifan	1	0	1
HIF-2alpha Inhibitor HS-10516	1	0	1

Drug classes tested here Alkylating agents 3 open · Antimetabolites 1 open · Antimitotic agents 4 · Tyrosine kinase inhibitors (TKIs) 4

Coming up

3phase 3 studies under way

9studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

All 9, phase 3 first

Dec 2026International Society of Paediatric Oncology (SIOP) PNET 5 Medulloblastoma · Phase 3 · Universitätsklinikum Hamburg-Eppendorf
Sep 2027A Phase 3 Study of Ersodetug in Patients With Tumor Hyperinsulinism · Phase 3 · Rezolute
Dec 2026Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors · University of Wisconsin, Madison
Feb 2027C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B) · Baylor College of Medicine
Mar 2027Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms · Jazz Pharmaceuticals
May 2027Study of B7-H3-Specific CAR T Cell Locoregional Immunotherapy for Diffuse Intrinsic Pontine Glioma/Diffuse Midline Glioma and Recurrent or Refractory Pediatric Central Nervous System Tumors · Seattle Children's Hospital
Jun 2027Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas · Cellectar Biosciences, Inc.
Jul 2027Agnostic Therapy in Rare Solid Tumors · Instituto do Cancer do Estado de São Paulo
Aug 2027GPC2-CAR T Cell Therapy for Relapsed or Refractory Medulloblastoma in Children and Young Adults · Stanford University

Who these studies take

Of the 19 Neuroectodermal Tumors, Primitive studies recruiting now, 7 (37%) set no upper age limit and 10 (53%) stop at 75 or younger. 15 (79%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 1 (5%) take healthy volunteers.

Recruiting studies that take each age, of 19
Age	Women	Men
10	12 (63%)	12 (63%)
18	18 (95%)	18 (95%)
30	11 (58%)	11 (58%)
40	9 (47%)	9 (47%)
50	9 (47%)	9 (47%)
65	9 (47%)	9 (47%)
75	9 (47%)	9 (47%)
85	8 (42%)	8 (42%)

Across all 120 studies, recruiting or not: 42% stop at 75 or younger and 38% at 65; 53% take children; 1% are for women only and 1% for men only; 3% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Neuroectodermal Tumors, Primitive studies take

Of 21 phase 1 interventional studies under Neuroectodermal Tumors, Primitive, half reached primary completion within 65 months of starting, counting those still running.

Start to primary completion	Every sponsor	Industry	Non-industry
Phase 1	65 mo54–134 · 21 studies	—	—

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 120. Browse all 120 → or search them.